Inhibitors of mTOR/PI3K (gedatolisib, AZD2014, LY3023414), G2M checkpoint (AZD7762, PHA-793887, AT7519), and NAMPT/glycolysis (FK866, STF-118804) effectively reduced the viability of each T-ALL cell line at nanomolar-range doses. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.